Literature DB >> 6814901

Controlled trials in epilepsy: a review.

L Gram, K D Bentsen, J Parnas, H Flachs.   

Abstract

A comprehensive review, evaluating 51 randomized double-blind controlled studies, covering different aspects of epileptology, is presented. Trials were grouped according to the investigated topic and for each group an attempt was made to derive an overall conclusion. The majority of studies investigated antiepileptic drug treatments. Other topics were: psychotropic effect of antiepileptic drugs, folic acid and vitamin D administration in epilepsy, and EEG investigations. A cross-sectional analysis of items such as designs, patient sampling principles, recording of effect parameters and side effects, concomitant treatments, and statistical evaluations demonstrated that cross-over designs, investigating fixed dosage schedules, were extensively used. Less than half of these studies included a washout period between treatments, complicating the interpretation of the obtained results. The vast majority of studies involved only chronic patients; and marked heterogeneity in patient selection with respect to age, seizure type, and mental status, and severity of epilepsy was observed. Classifications of seizures varied between the studies. The most prominent effect parameter was seizure frequency. The use of heterogeneous patient samples frequently necessitated equalization of widely different seizure types in order to perform statistical analyses. The mean duration of trials was 6 months, precluding evaluation of chronic toxicity. The majority of studies recorded side effects, but data collection was rather unsystematic and statistical evaluation was seldom applied. Most studies were add-on trials, and since concomitant treatment was frequently changed during the investigations, it was difficult to evaluate the influence of this variable. A correlation analysis across trials demonstrated, among other things, that the common assumption that short controlled trials provide too optimistic results, could not be substantiated. This survey provides no firm indication of which drug is more suitable for which seizure type.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6814901     DOI: 10.1111/j.1528-1157.1982.tb05437.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  10 in total

Review 1.  Drug treatment of epilepsy in the 1990s. Achievements and new developments.

Authors:  A Sabers; L Gram
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

2.  Progress in the treatment of epilepsy.

Authors:  C D Binnie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-04       Impact factor: 10.154

3.  The comparative efficacy of antiepileptic drugs for partial and tonic-clonic seizures.

Authors:  D Chadwick; D M Turnbull
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-11       Impact factor: 10.154

Review 4.  Antiepileptic drug toxicity: definition and mechanism of action.

Authors:  E Beghi; R Di Mascio
Journal:  Ital J Neurol Sci       Date:  1986-04

5.  Psychomotor impairment and anticonvulsant therapy in adult epileptic patients.

Authors:  M J Brodie; E McPhail; G J Macphee; J G Larkin; J M Gray
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 6.  Drug treatment of epilepsy. Outlines, criticism and perspectives.

Authors:  E Beghi; R Di Mascio; G Tognoni
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

7.  Preliminary evaluation of potential anti-epileptic drugs by single dose electrophysiological and pharmacological studies in patients.

Authors:  C D Binnie
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

8.  An immunodominant haptenic epitope of carbamazepine detected in serum from patients given long-term treatment with carbamazepine without allergic reaction.

Authors:  M Igarashi; N Hosoda; Y Bando; K Shimanuki; W Sunaoshi; H Shirai; H Miura
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

9.  Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial.

Authors:  A J Heller; P Chesterman; R D Elwes; P Crawford; D Chadwick; A L Johnson; E H Reynolds
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-01       Impact factor: 10.154

Review 10.  The management of epilepsy in the 1990s. Acquisitions, uncertainties and priorities for future research.

Authors:  E Beghi; E Perucca
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.